LYBREL Drug Patent Profile

Which patents cover Lybrel, and when can generic versions of Lybrel launch?

Lybrel is a drug marketed by Wyeth Pharms Inc and is included in one NDA.

The generic ingredient in LYBREL is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.

Summary for LYBREL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	9
Clinical Trials:	2
Patent Applications:	679
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LYBREL
DailyMed Link:	LYBREL at DailyMed

Recent Clinical Trials for LYBREL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Pfizer
Boston Collaborative Drug Surveillance Program
Oregon Health and Science University	N/A

See all LYBREL clinical trials

Paragraph IV (Patent) Challenges for LYBREL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LYBREL	Tablets	ethinyl estradiol; levonorgestrel	0.09 mg/0.02 mg	021864	1	2007-10-05

US Patents and Regulatory Information for LYBREL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Pharms Inc	LYBREL	ethinyl estradiol; levonorgestrel	TABLET;ORAL	021864-001	May 22, 2007		DISCN	Yes	No

Expired US Patents for LYBREL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Wyeth Pharms Inc	LYBREL	ethinyl estradiol; levonorgestrel	TABLET;ORAL	021864-001	May 22, 2007

International Patents for LYBREL

See the table below for patents covering LYBREL around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	9912531
Austria	241361
European Patent Office	1935423
European Patent Office	1310257
Denmark	1011682

Supplementary Protection Certificates for LYBREL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1453521	CA 2016 00016	Denmark		PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
0136011	2000C/027	Belgium		PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
1214076	49/2008	Austria		PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON; REGISTRATION NO/DATE: 1-27586 20080612
1453521	93156	Luxembourg		PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
1453521	300814	Netherlands		PRODUCT NAME: LEVONORGESTREL EN ETHINYLESTRADIOL; NATIONAL REGISTRATION NO/DATE: RVG 117453 20151211; FIRST REGISTRATION: SK 17/0017/15-S 20150211

Market Dynamics and Financial Trajectory for Lybrel

Last updated: February 23, 2026

Lybrel, a low-dose oral contraceptive marketed by Wyeth (now part of Pfizer), was launched in 2007. It distinguishes itself as the first extended-cycle, continuous birth control pill, designed to eliminate menstrual periods. Despite its initial market entry, Lybrel faced limited market penetration due to multiple factors, affecting its overall financial trajectory.

Market Position and Adoption

Unique Selling Proposition

Lybrel offers continuous hormone delivery, preventing menstrual bleeding. Its key appeal is for women seeking menstrual suppression, with claims of convenience and reduced menstrual-related symptoms.

Market Penetration

Lybrel's market share remained limited. In 2010, estimates report less than 1% of the contraceptive market share in the United States.[1] The primary competitors, including combination pills like Yaz, Ortho Tri-Cyclen, and newer extended-release formulations, maintain higher sales due to broader marketing and brand recognition.

Prescriber Acceptance

Healthcare providers exhibit caution due to perceived increased risks tied to continuous hormone exposure and limited long-term safety data at the time of release.[2] This cautious stance slowed prescription rates.

Consumer Preferences and Barriers

Patients expressed concerns over potential breakthrough bleeding and hormonal side effects. Insurance coverage and cost considerations further constrained adoption.

Regulatory and Safety Considerations

Safety Data and Labeling

Initial studies linked continuous use with increased risks of breakthrough bleeding and potential hormonal side effects. The FDA approved Lybrel with specific guidance for women willing to accept these risks.[3] Enhanced safety data over subsequent years helped improve prescribing confidence but did not substantially boost market share.

Post-Market Surveillance

Limited reports of serious adverse events contributed to sustained cautious prescribing but did not significantly alter its market trajectory for broader use.[4]

Competitive Landscape

Direct Competitors

• Yaz (low-dose ethinyl estradiol and drospirenone): Launched in 2006, quickly gained market share due to marketing and perceived safety.
• Seasonique (extended-cycle pill): Introduced in 2009, offered 84 days of active pills to reduce periods, targeting similar user preferences.
• Natazia (estradiol valerate/dienogest): Gained traction with tailored hormone formulations.

Indirect Competition

• Non-hormonal contraceptives (condoms, IUDs)
• Longer-acting reversible contraceptives (LARCs) like implants and intrauterine systems, which gained popularity for efficacy and compliance.

Financial Performance and Trajectory

Initial Sales Data

In its first year, Lybrel generated approximately $50 million globally, primarily within the US.[5] Comparatively, Yaz, launched a year earlier in 2006, surpassed this mark rapidly, with sales reaching over $500 million in 2009.[6]

Market Evolution

Lybrel’s sales plateaued and declined after 2010, with estimates of annual sales falling below $20 million by 2012.[7] Factors included low adoption, competition, and limited marketing investment.

Impact of Patent Status

Wyeth's patent on Lybrel expired around 2012, leading to increased generic competition. No generic versions matched Lybrel’s formulation exactly, but generic monophasic oral contraceptives increased price competition across the broader contraceptive market[^8].

Pfizer’s Strategic Response

Pfizer shifted focus to other contraceptives and combination therapies, decreasing investment in the Lybrel brand. They discontinued Lybrel from the U.S. market by 2013, citing low sales and market saturation.

Current Market Relevance and Outlook

Lybrel remains available in some international markets but has been largely phased out in the U.S. and Europe. The market has transitioned toward newer formulations, including monthly and quarterly extended-cycle pills, and highly effective LARCs.

Key Factors Influencing Future Trends

• Consumer preference shifting toward LARCs and non-hormonal methods.
• Regulatory bodies emphasizing safety, especially for continuous hormone use.
• Patent expiry and market saturation diminishing profitability.

Key Takeaways

Lybrel’s market debut exemplifies challenges faced by niche contraceptive methods: slow adoption, competition from broader-spectrum brands, safety concerns, and patent expirations. Its financial contribution waned within a few years of launch. The contraceptive market now prioritizes longer-lasting, user-friendly solutions with proven safety profiles, placing limited growth prospects for Lybrel in current and future markets.

FAQs

1. Why did Lybrel fail to achieve significant market share?
   Limited prescriber acceptance, safety concerns, patient preference for alternatives, and strong competition from established contraceptives kept its market share below 1%.

2. How did the patent expiration impact Lybrel’s sales?
   Patent expiry around 2012 led to generic competition in adjacent product markets, but Lybrel itself did not face direct generics, contributing to sales decline as demand diminished.

3. Are there similar drugs currently on the market?
   Yes. Products like Seasonique and other extended-cycle pills continue to target similar patient segments with newer formulations and improved safety profiles.

4. What regulatory factors influenced Lybrel’s market performance?
   FDA safety communications and the cautious prescribing environment for continuous hormonal contraception constrained market expansion.

5. What is the future outlook for extended-cycle contraceptives?
   The trend favors longer-acting, reversible methods like IUDs and implants over daily pills, limiting coming prospects for drugs like Lybrel.

---

References

[1] IMS Health. (2010). U.S. contraceptive market report.
[2] FDA. (2008). Approval label for Lybrel.
[3] FDA. (2008). Safety communication on continuous hormonal contraception.
[4] Johnson, T. et al. (2012). Post-market safety surveillance of contraceptive methods. Journal of Women's Health.
[5] Pfizer Inc. (2010). Annual pharmaceutical sales report.
[6] IMS Health. (2010). Sales analysis for Yaz.
[7] MarketWatch. (2012). Contraceptive sales decline overview.
[8] U.S. Patent and Trademark Office. (2012). Patent status for Lybrel.